Overview

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)

Status:
Completed
Trial end date:
2018-03-27
Target enrollment:
Participant gender:
Summary
This will be a randomised, crossover, double-blind, double-dummy, active-controlled, multicentre, phase II proof-of-concept study in Parkinson's Disease (PD) patients with end-of-dose wearing-off (motor fluctuations).
Phase:
Phase 2
Details
Lead Sponsor:
Orion Corporation, Orion Pharma
Treatments:
Carbidopa
Entacapone
Levodopa